Phase II Trial of Eribulin and Lenvatinib in Advanced Solid Tumors (CTMS 15-2139)
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Eribulin (Primary) ; Lenvatinib (Primary)
- Indications Breast cancer; Non-small cell lung cancer; Solid tumours
- Focus Therapeutic Use
- 02 Apr 2018 Planned End Date changed from 1 Jan 2018 to 1 Mar 2019.
- 02 Apr 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Mar 2019.
- 21 Jul 2016 Status changed from not yet recruiting to recruiting.